AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol (May 17, 2005). doi:10.1152/ajprenal.00065.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/5/F998    most recent
00065.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugaru, E.
Right arrow Articles by Taiji, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugaru, E.
Right arrow Articles by Taiji, M.
Submitted on February 15, 2005
Accepted on May 15, 2005

SMP-534 inhibits TGF-{beta} induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis

Eiji Sugaru1, Mutsuko Sakai1, Kazuhiko Horigome2, Teruhisa Tokunaga3, Makoto Kitoh3, W. Ewan Hume3, Ryu Nagata3, Tsutomu Nakagawa1, and Mutsuo Taiji1*

1 Discovery Research Laboratories I, Sumitomo Pharmaceuticals Research Division, Osaka, Osaka, Japan
2 Genomic Research Laboratories, Sumitomo Pharmaceuticals Research Division, Osaka, Osaka, Japan
3 Chemical Research Laboratories, Sumitomo Pharmaceuticals Research Division, Osaka, Osaka, Japan

* To whom correspondence should be addressed. E-mail: taiji{at}sumitomopharm.co.jp.

Transforming growth factor-{beta} (TGF-{beta}) is a potent fibrotic factor responsible for the synthesis of extracellular matrix (ECM) and is implicated as the major determinant in pathogenesis of chronic fibroses, including kidney. The novel small compound, SMP-534, reduced ECM production induced by TGF-{beta} in fibroblast cells. SMP-534 inhibited TGF-{beta}-induced p38 mitogen activated protein kinase (p38) activation but did not inhibit epidermal growth factor (EGF)-induced extracellular signal-related kinase (ERK) activation. We also found that oral administration of SMP-534 dose-dependently lowered hydroxyproline contents in the cortical region of the kidney in rat anti-Thy-1 nephritis models. In periodic acid-Schiff staining of kidney sections, ECM accumulation was reduced by SMP-534 treatment. These data indicate that SMP-534 has potential in therapy for fibrotic diseases, including nephropathy.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
E. Sugaru, T. Nakagawa, M. Ono-Kishino, J. Nagamine, T. Tokunaga, M. Kitoh, W. E. Hume, R. Nagata, and M. Taiji
SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
Am J Physiol Renal Physiol, April 1, 2006; 290(4): F813 - F820.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Boxall, S. T. Holgate, and D. E. Davies
The contribution of transforming growth factor-{beta} and epidermal growth factor signalling to airway remodelling in chronic asthma
Eur. Respir. J., January 1, 2006; 27(1): 208 - 229.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.